[{"id":"f1a618a2-7612-4fa2-a348-d6930286a2b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079360","created_at":"2021-10-15T14:53:03.049Z","updated_at":"2024-07-02T16:35:52.523Z","phase":"Phase 2","brief_title":"Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer","source_id_and_acronym":"NCT05079360","lead_sponsor":"Veru Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • exemestane • sabizabulin (VERU-111)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 05/26/2024","study_completion_date":" 05/26/2024","last_update_posted":"2023-03-24"},{"id":"fea016be-44ac-4b44-bd4f-d532bd9981a8","acronym":"VERU-111","url":"https://clinicaltrials.gov/study/NCT05008510","created_at":"2021-08-17T13:52:55.952Z","updated_at":"2024-07-02T16:36:17.401Z","phase":"Phase 2","brief_title":"P2 Clinical Efficacy \u0026 Safety Study of V-111 Monotherapy \u0026 Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .","source_id_and_acronym":"NCT05008510 - VERU-111","lead_sponsor":"Veru Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • sabizabulin (VERU-111)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 07/30/2022","primary_completion_date":" 07/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-02-08"}]